| Literature DB >> 35563673 |
Monika Gudowska-Sawczuk1, Barbara Mroczko1,2.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes Coronavirus Disease 19 (COVID-19), a disease that has affected more than 500 million people worldwide since the end of 2019. Due to its high complications and death rates, there is still a need to find the best therapy for SARS-CoV-2 infection. The dysregulation of the inflammatory response in COVID-19 plays a very important role in disease progression. It has been observed that abnormal activity of Nuclear Factor kappa B (NF-κB) is directly associated with, inter alia, increased synthesis of proinflammatory factors. Therefore, this review paper focuses on the functions of NF-κB in the development of SARS-CoV-2 infection and potential application of NF-κB inhibitors in COVID-19 immunotherapy. A comprehensive literature search was performed using the MEDLINE/PubMed database. In the current review, it is highlighted that NF-κB plays important functions in the modulation of an adaptive inflammatory response, including inducing the expression of proinflammatory genes. Increased activation of NF-κB in SARS-CoV-2 infection was observed. The association between NF-κB activation and the expression of SARS-CoV-2 structural and non-structural proteins were also reported. It was observed that modulation of NF-κB using, e.g., traditional Chinese medicine or glucocorticosteroids resulted in decreased synthesis of proinflammatory factors caused by SARS-CoV-2 infection. This review summarizes the role of NF-κB in COVID-19 and describes its potential immunotherapeutic target in treatment of SARS-CoV-2 infection. However, indisputably more studies involving patients with a severe course of COVID-19 are sorely needed.Entities:
Keywords: COVID-19; Nuclear Factor kappa B (NF-κB); SARS-CoV-2; inflammation; inflammatory factors
Mesh:
Substances:
Year: 2022 PMID: 35563673 PMCID: PMC9101079 DOI: 10.3390/ijms23095283
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Figure 1The role of Nuclear Factor kappa B in SARS-CoV-2 infection.
Figure 2The PRISMA Flow Diagram.
Proposed therapeutical doses of selected drugs.
| Drug | Tested Doses | References |
|---|---|---|
| Nanocurcumin | 0.001, 0.01, 0.1, 0.2, 0.5, 5.0 μM | [ |
|
| 6.25, 12.5, 25 μg/mL | [ |
| Garcinoic acid | 1.25, 2.5 and 5 μM | [ |
| Naringenin | 50.0, 150.0 mg/kg | [ |
| AUY-922, AT13387 | 2.0 μM | [ |
| Qingwenzhike | 3.0, 6.0, and 12.0 g/kg/day; 71.5 g/day | [ |
| Liu Shen capsule | 0.50, 1.00, 2.00 μg/mL | [ |
| Yindan Jiedu granules | 12.0 and 24.0 g/day | [ |
| Cangma Huadu granules | 12.1, 6.05 and 3.03 g/kg/day | [ |
| Jinzhen granule | 224, 448, 896 mg/kg/day | [ |
| Diosmectite | 100 mg/mL | [ |